Compare ARQT & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARQT | HLNE |
|---|---|---|
| Founded | 2016 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | 2020 | 2017 |
| Metric | ARQT | HLNE |
|---|---|---|
| Price | $20.44 | $85.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $34.00 | ★ $156.78 |
| AVG Volume (30 Days) | ★ 1.8M | 880.7K |
| Earning Date | 05-06-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 2.44% |
| EPS Growth | ★ 88.79 | 41.64 |
| EPS | N/A | ★ 3.98 |
| Revenue | $376,072,000.00 | ★ $712,963,000.00 |
| Revenue This Year | $34.85 | $9.69 |
| Revenue Next Year | $29.39 | $15.81 |
| P/E Ratio | ★ N/A | $21.23 |
| Revenue Growth | ★ 91.34 | 28.73 |
| 52 Week Low | $12.72 | $84.07 |
| 52 Week High | $31.77 | $179.19 |
| Indicator | ARQT | HLNE |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 36.47 |
| Support Level | $19.60 | N/A |
| Resistance Level | $24.56 | $104.22 |
| Average True Range (ATR) | 1.27 | 3.36 |
| MACD | -0.20 | -0.17 |
| Stochastic Oscillator | 23.32 | 21.56 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.